Rench Wealth Management’s Estee Lauder EL Stock Holding History

Rench Wealth Management’s Portfolio EL Stock Details EL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-694	Closed	-$257K	–	41
2021 Q4	$257K	Hold	694	–	–	0.12%	40
2021 Q3	$208K	Hold	694	–	–	0.1%	41
2021 Q2	$221K	Hold	694	–	–	0.11%	40
2021 Q1	$202K	Buy	+694	New	+$190K	0.11%	38

Other funds holding EL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Rench Wealth Management's EL Position: Q1 2022 in Review

Rench Wealth Management sold out of Estee Lauder (EL) in Q1 2022, closing a stake of 694 shares — an estimated $257K sold.

Rench Wealth Management first reported a position in EL in Q1 2021 and held it in 4 quarters. The position peaked at $257K in Q4 2021. 1,205 funds tracked by Wall St. Rank hold EL as of Q1 2022.

Rench Wealth Management reported no remaining Estee Lauder position as of Q1 2022 after selling out during the quarter.
Rench Wealth Management sold 694 Estee Lauder shares in Q1 2022, an estimated $257K.
Rench Wealth Management first reported a position in Estee Lauder in Q1 2021 and held it in 4 quarters.
Rench Wealth Management's Estee Lauder position peaked at $257K in Q4 2021.
1,205 funds tracked by Wall St. Rank held Estee Lauder as of Q1 2022.

Based on Rench Wealth Management's 13F filing for Q1 2022, filed 13 May 2022.